Abbott Laboratories (ABT): Price Target and June Short Interest Disclosure

Abbott Laboratories (ABT) : The most positive equity analysts on Abbott Laboratories (ABT) expects the shares to touch $50, whereas, the least positive believes that the stock will trade at $45 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $47.55 with an expected fluctuation of $1.75 from the mean.

Abbott Laboratories (ABT) has witnessed a rise of 15.5% or 8,163,168 shares in its short figure. The short interest augmentation took it from 52,754,358 on June 15,2016 to 60,917,526 on June 30,2016. In terms of floated shares, the short interest was calculated to be 4.2%. The days to cover are 6 given that the daily volume averaged 10,441,003 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, Equity Analysts at the Brokerage Firm, Edward Jones, upgrades their rating on the shares of Abbott Laboratories (NYSE:ABT). Edward Jones has a Buy rating on the shares. Previously, the analysts had a Hold rating on the shares. The rating by the firm was issued on June 21, 2016.


Abbott Laboratories (NYSE:ABT): stock turned positive on Thursday. Though the stock opened at $42.34, the bulls momentum made the stock top out at $42.42 level for the day. The stock recorded a low of $42.02 and closed the trading day at $42.28, in the green by 0.74%. The total traded volume for the day was 9,011,856. The stock had closed at $41.97 in the previous days trading.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.